Antibiotic prophylaxis for preventing post solid organ transplant tuberculosis

Risk-benefit analysis of isoniazid monotherapy to prevent tuberculosis in patients with rheumatic diseases exposed to prolonged, high-dose glucocorticoids

“…This result is consistent with previous reports suggesting that impaired cellular immunity caused by steroid treatment signi cantly increases the risk of TB [7,20]. However, INH treatment to prevent TB did not reduce its 1-year incidence, contrary to its proven e cacy in HIV-positive or transplant patients [21][22][23][24].…”

Risk-benefit analysis of isoniazid monotherapy to prevent tuberculosis in patients with rheumatic diseases exposed to prolonged, high-dose glucocorticoids

“…This result is consistent with previous reports suggesting that impaired cellular immunity caused by steroid treatment signi cantly increases the risk of TB [7,20]. However, INH treatment to prevent TB did not reduce its 1-year incidence, contrary to its proven e cacy in HIV-positive or transplant patients [21][22][23][24].…”

The burden of cutaneous disease in solid organ transplant recipients of color

“…Acne may be caused by corticosteroids, cyclosporine, mycophenolic acid agents, and sirolimus 74 . Patients originating from high‐incidence countries receive antituberculous prophylaxis with isoniazid for at least 1 year posttransplant, which is well known to provoke AEs 75,76 . We observed increased incidence of dermatitis in black OTRs.…”

Mycobacterium tuberculosis after solid organ transplantation: A review of more than 2000 cases

“…Prophylaxis is not fool proof, and patients on prophylaxis can still develop TB disease, as reported in some cohorts . However, a recent systematic review comprising of only kidney recipients confirms that isoniazid prophylaxis reduced the risk of post‐transplant TB (RR 0.35 95% CI 0.14 to 0.89). As such, we recommend isoniazid prophylaxis should be offered to recipients fulfilling any of the following criteria—tuberculin skin test >5 mm or recent conversion, radiographic evidence of old TB without prophylaxis, history of inadequate prophylaxis, and receipt of an allograft from a high‐risk donor .…”

“…Prophylaxis is not fool proof, and patients on prophylaxis can still develop TB disease, as reported in some cohorts. 166,174 However, a recent systematic review 196 Risk factors for MDRTB are close contact with a known MDRTB case and birth in a MDRTB-endemic country. In our cohort, 2 were from an endemic country, 71,103 one had prolonged history of incarceration, 35 and one had no known risk factors for MDRTB.…”

Risk-benefit analysis of isoniazid monotherapy to prevent tuberculosis in patients with rheumatic diseases exposed to prolonged, high-dose glucocorticoids

“…This result is consistent with previous reports suggesting that impaired cellular immunity caused by steroid treatment signi cantly increases the risk of TB [7,20]. However, INH treatment to prevent TB did not reduce its 1-year incidence, contrary to its proven e cacy in HIV-positive or transplant patients [21][22][23][24].…”

The burden of cutaneous disease in solid organ transplant recipients of color

“…Acne may be caused by corticosteroids, cyclosporine, mycophenolic acid agents, and sirolimus 74 . Patients originating from high‐incidence countries receive antituberculous prophylaxis with isoniazid for at least 1 year posttransplant, which is well known to provoke AEs 75,76 . We observed increased incidence of dermatitis in black OTRs.…”

Mycobacterium tuberculosis after solid organ transplantation: A review of more than 2000 cases

“…Prophylaxis is not fool proof, and patients on prophylaxis can still develop TB disease, as reported in some cohorts . However, a recent systematic review comprising of only kidney recipients confirms that isoniazid prophylaxis reduced the risk of post‐transplant TB (RR 0.35 95% CI 0.14 to 0.89). As such, we recommend isoniazid prophylaxis should be offered to recipients fulfilling any of the following criteria—tuberculin skin test >5 mm or recent conversion, radiographic evidence of old TB without prophylaxis, history of inadequate prophylaxis, and receipt of an allograft from a high‐risk donor .…”

“…Prophylaxis is not fool proof, and patients on prophylaxis can still develop TB disease, as reported in some cohorts. 166,174 However, a recent systematic review 196 Risk factors for MDRTB are close contact with a known MDRTB case and birth in a MDRTB-endemic country. In our cohort, 2 were from an endemic country, 71,103 one had prolonged history of incarceration, 35 and one had no known risk factors for MDRTB.…”

Risk-benefit analysis of isoniazid monotherapy to prevent tuberculosis in patients with rheumatic diseases exposed to prolonged, high-dose glucocorticoids

“…This result is consistent with previous reports suggesting that impaired cellular immunity caused by steroid treatment signi cantly increases the risk of TB [7,20]. However, INH treatment to prevent TB did not reduce its 1-year incidence, contrary to its proven e cacy in HIV-positive or transplant patients [21][22][23][24].…”

The burden of cutaneous disease in solid organ transplant recipients of color

“…Acne may be caused by corticosteroids, cyclosporine, mycophenolic acid agents, and sirolimus 74 . Patients originating from high‐incidence countries receive antituberculous prophylaxis with isoniazid for at least 1 year posttransplant, which is well known to provoke AEs 75,76 . We observed increased incidence of dermatitis in black OTRs.…”

Mycobacterium tuberculosis after solid organ transplantation: A review of more than 2000 cases

“…Prophylaxis is not fool proof, and patients on prophylaxis can still develop TB disease, as reported in some cohorts . However, a recent systematic review comprising of only kidney recipients confirms that isoniazid prophylaxis reduced the risk of post‐transplant TB (RR 0.35 95% CI 0.14 to 0.89). As such, we recommend isoniazid prophylaxis should be offered to recipients fulfilling any of the following criteria—tuberculin skin test >5 mm or recent conversion, radiographic evidence of old TB without prophylaxis, history of inadequate prophylaxis, and receipt of an allograft from a high‐risk donor .…”

“…Prophylaxis is not fool proof, and patients on prophylaxis can still develop TB disease, as reported in some cohorts. 166,174 However, a recent systematic review 196 Risk factors for MDRTB are close contact with a known MDRTB case and birth in a MDRTB-endemic country. In our cohort, 2 were from an endemic country, 71,103 one had prolonged history of incarceration, 35 and one had no known risk factors for MDRTB.…”